Lively Finance Debate Doesn’t Move Party Positions On Drug Price Controls

By John Wilkerson / March 16, 2022 at 5:39 PM

A Senate Finance Committee hearing on drug prices Wednesday (March 16) did not seem to move members of either party off their dug-in positions, but committee members made some interesting comments: Sen. Chuck Grassley (R-IA) said his bipartisan bill from 2019 has a better chance of passing in a Democratic-controlled Congress; Chair Ron Wyden (D-OR) said the U.S. health care system forces patients to beg for drugs; Sen. Pat Toomey highlighted insulin as an example of the free market working; and a GOP-invited witness outlined a counter argument to Democrats’ assertion that their drug pricing plan would help curb inflation.



Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.